1. Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
   Vladimer Darsalia et al, 2019, Frontiers in Neurology CrossRef
2. Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients
   Chin-Hsiao Tseng, 2021, Frontiers in Endocrinology CrossRef
3. Antidiabetic treatment on memory and spatial learning: From the pancreas to the neuron
   Eleni Xourgia et al, 2019, World Journal of Diabetes CrossRef
4. GLP-1’s role in neuroprotection: a systematic review
   Damla Erbil et al, 2019, Brain Injury CrossRef
5. Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
   Xin Jiang et al, 2024, Frontiers in Pharmacology CrossRef
6. Effect of Vildagliptin on Cognitive Deficits in an Experimental Model of Alzheimer’s Disease
   Devasrita Dash et al, 2022, Biomedical and Pharmacology Journal CrossRef
7. Targeting Insulin Resistance to Treat Cognitive Dysfunction
   Anit Tyagi et al, 2021, Molecular Neurobiology CrossRef
8. Diabetic Theory in Anti-Alzheimer’s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents
   Agnieszka Jankowska et al, 2020, Current Medicinal Chemistry CrossRef
9. Link between Diabetes and Alzheimer’s Disease Due to the Shared Amyloid Aggregation and Deposition Involving Both Neurodegenerative Changes and Neurovascular Damages
   Gabriela Dumitrita Stanciu et al, 2020, Journal of Clinical Medicine CrossRef